hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06341764 id: CITATION id: 7/23 type: OTHER domain: IRCCS I.N.T. "G. Pascale" briefTitle: Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma overallStatus: RECRUITING date: 2023-09-01 date: 2024-09 date: 2025-09 date: 2024-04-02 date: 2024-04-02 name: National Cancer Institute, Naples class: OTHER briefSummary: Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery. conditions: Cholangiocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 38 type: ESTIMATED name: Durvalumab 1120 mg name: Durvalumab 1500 mg name: Tremelimumab i.v. at 300 mg name: Cisplatin (CDDP) 25 mg/mq i.v name: Gemcitabine (GEM) 1000 mg/mq i.v. measure: Recurrence rate of CCA measure: Rate of R0 resections measure: Radiologic responses measure: Pathologic responses measure: Toxicity assessed measure: PFS measure: OS measure: Exploratory objectives measure: Exploratory objectives sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale status: RECRUITING city: Napoli state: Italia zip: 80131 country: Italy name: Alessandro Ottaiano role: CONTACT phone: 08117770344 email: a.ottaiano@istitutotumori.na.it name: Alessandro Ottaiano role: PRINCIPAL_INVESTIGATOR name: Guglielmo Nasti role: SUB_INVESTIGATOR name: Francesco Izzo role: SUB_INVESTIGATOR name: Andrea Belli role: SUB_INVESTIGATOR lat: 40.85216 lon: 14.26811 facility: Ospedale Cardarelli, Napoli status: NOT_YET_RECRUITING city: Napoli state: Italia zip: 80131 country: Italy name: Giovanni Vennarecci role: CONTACT phone: 0817472372 email: giovanni.vennarecci@aocardarelli.it name: Giovanni Vennarecci role: PRINCIPAL_INVESTIGATOR lat: 40.85216 lon: 14.26811 facility: Università di Napoli "Federico II", Napoli status: NOT_YET_RECRUITING city: Napoli state: Italia zip: 80131 country: Italy name: Roberto Bianco role: CONTACT phone: 0817462061 email: robianco@unina.it name: Roberto Bianco role: PRINCIPAL_INVESTIGATOR lat: 40.85216 lon: 14.26811 facility: Ospedale san Camillo Forlanini/Spallanzani, Roma status: NOT_YET_RECRUITING city: Roma state: Italia zip: 00152 country: Italy name: Viola Barucca role: CONTACT phone: 3391333211 email: viola.barucca.scf@gmail.com name: Viola Barucca role: PRINCIPAL_INVESTIGATOR lat: 41.89193 lon: 12.51133 facility: Ospedale Mauriziano, Umberto I° status: NOT_YET_RECRUITING city: Torino state: Italia zip: 10128 country: Italy name: Massimo Di Maio role: CONTACT phone: 0115082032 email: massimo.dimaio@unito.it name: Massimo Di Maio role: PRINCIPAL_INVESTIGATOR lat: 45.07049 lon: 7.68682 facility: Università di Verona, Ospedale Borgoroma, Verona status: NOT_YET_RECRUITING city: Verona state: Italia zip: 37134 country: Italy name: Alessandra Auriemma role: CONTACT phone: 3483148292 email: alessandra.auriemma@aovr.veneto.it name: Alessandra Auriemma role: PRINCIPAL_INVESTIGATOR lat: 45.4299 lon: 10.98444 hasResults: False
nctId: NCT06341751 id: 2024-00393-01 briefTitle: Psychological Treatment for Persistent Fatigue overallStatus: RECRUITING date: 2024-04-11 date: 2024-12 date: 2025-04 date: 2024-04-02 date: 2024-04-12 name: Karolinska Institutet class: OTHER name: Forte name: The Swedish Research Council name: Region Stockholm briefSummary: This is a non-randomized pilot study to investigate the feasibility and acceptability of a transdiagnostic psychological intervention for primary care patients in Region Stockholm, Sweden, who suffer from persistent and disabling fatigue. conditions: Fatigue conditions: Fatigue Syndrome, Chronic conditions: Exhaustion; Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Psychological treatment for persistent fatigue measure: Treatment adherence and completion measure: Treatment credibility measure: Patient satisfaction measure: Working alliance measure: Negative effects of treatment measure: Open-ended questions regarding treatment content and presentation measure: Feasibility of study inclusion procedures and data-collection measure: Fatigue severity, primary self-rated symptom outcome measure: Problems concentrating measure: Reduced physical activity measure: Reduced motivation measure: Depressive symptoms measure: Somatic symptoms measure: General anxiety measure: Insomnia measure: Perceived Stress measure: Burnout measure: Self-rated health measure: Cognitive and behavioral responses to symptoms measure: General self-efficacy measure: Functional disability measure: Work and Social Adjustment measure: Treatment fidelity measure: Evaluation of participants' experience of treatment measure: Acceptability, Appropriateness, and Feasibility from the perspective of the clinic sex: ALL minimumAge: 18 Years maximumAge: 67 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gustavsberg University Primary Care Clinic status: RECRUITING city: Stockholm zip: 134 40 country: Sweden name: Jacob Andersson Emad, MD, PhD role: CONTACT phone: 0736566876 phoneExt: +46 email: jacob.andersson-emad@regionstockholm.se name: Kersti Ejeby, MD, PhD role: CONTACT phone: 0704848104 phoneExt: +46 email: kersti.ejeby@regionstockholm.se lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06341738 id: 421/215/404.102.28/VI/2023 briefTitle: The Efficacy of Digital Educational Interventions on Parental HPV Knowledge and Attitude, and Their Children's Vaccination Rates overallStatus: COMPLETED date: 2023-07-05 date: 2024-02-01 date: 2024-02-29 date: 2024-04-02 date: 2024-04-02 name: Kaohsiung Medical University class: OTHER briefSummary: The goal of this clinical trial is to examine in the parental HPV knowledge and attitude, and their children's completion rates in Indonesia. The main question\[s\] it aims to answer are:
• Receive usual announcement regarding vaccine by staff conditions: Health Services Research studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 10 units are divided into 2 arms (e.g. intervention and control) by cluster randomisation using the number of units into a sealed envelope. the participants are unaware of which group they were placed in primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 374 type: ACTUAL name: Video education about HPV and HPV vaccine name: Electronic reminder messages name: Usual Information Service measure: Human Papillomavirus Knowledge Scale (HPV-KS) measure: Attitude towards HPV vaccine scale by Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS) measure: Vaccine completion rate sex: ALL minimumAge: 17 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Elementary school city: Ngawi state: East Java zip: 63271 country: Indonesia lat: -7.4038 lon: 111.4461 hasResults: False
nctId: NCT06341725 id: LinfoK EUS 2016 briefTitle: EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging overallStatus: TERMINATED date: 2018-02-15 date: 2018-02-15 date: 2018-09-11 date: 2024-04-02 date: 2024-04-02 name: Paolo Giorgio Arcidiacono, MD class: OTHER briefSummary: Aim of the study will be to investigate if Endoscopic Ultrasound (EUS) with elastography can be purposed between the routine staging examinations in patients with pancreatic adenocarcinoma without distant metastasis for the staging of lymph nodes status ("N" in TNM classification)
Secondary aim will be to register the prognosis (in terms of survival) of the patients with para-aortic and mediastinal pathological lymph nodes (related to a decreases survival in some series in literature) conditions: Pancreatic Adenocarcinoma conditions: Lymph Node Metastasis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 2 type: ACTUAL name: malignant lymph nodes measure: CONCORDANCE (PERCENTAGE) of pathological lymph nodes at EUS with elastography and surgical pathology report measure: OVERALL SURVIVAL (MONTHS) in metastatic lymph node presence measure: OVERALL SURVIVAL (MONTHS) in metastatic lymph node presence measure: OVERALL SURVIVAL (MONTHS) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS San Raffaele Hospital city: Milan country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06341712 id: CLIN-60000-461 id: 2023-506229-12-00 type: OTHER domain: Ipsen briefTitle: Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma acronym: CabOSTar overallStatus: NOT_YET_RECRUITING date: 2024-06-13 date: 2026-10-26 date: 2028-06-15 date: 2024-04-02 date: 2024-04-02 name: Ipsen class: INDUSTRY briefSummary: The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.
The estimated duration of the study for participants is 24 months, however a participant could remain in the study longer if demonstrating treatment benefit. conditions: Osteosarcoma conditions: Osteosarcoma in Children conditions: Osteosarcoma in Adolescents and Young Adults studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: Cabozantinib name: Best Supportive Care (BSC) name: Best Supportive Care (BSC) measure: Progression-free Survival (PFS) assessed by Blinded Independent Radiology Committee (BIRC) measure: Progression-free survival (PFS) rate assessed by BIRC measure: Objective response rate (ORR) assessed by BIRC measure: Disease control rate (DCR) assessed by BIRC measure: PFS assessed by investigator measure: PFS rate assessed by investigator measure: ORR assessed by investigator measure: DCR assessed by investigator measure: Overall survival (OS) measure: 1-year overall survival rate measure: Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Adverse Events of Special Interest (AESIs). measure: Area Under Curve (AUC) at steady state. measure: Average concentration (Cavg) at steady state measure: Minimum concentration (Cmin) at steady state measure: Maximal concentration (Cmax) at steady state measure: Acceptability and palatability in children and adolescents assessed using a horizontal visual assessment scale. measure: Change from baseline in score for all Paediatric QoL Inventory (PedsQL) Scales including Generic Core Scales and Cancer Modules. measure: Change from baseline in European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) (EORTC QLQ-C30) for adult participants sex: ALL minimumAge: 5 Years maximumAge: 30 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06341699 id: 05C308 briefTitle: Study of the Steroid Hormone Milieu in Obese Patients acronym: MiSterO overallStatus: RECRUITING date: 2023-05-16 date: 2024-12-31 date: 2024-12-31 date: 2024-04-02 date: 2024-04-02 name: Istituto Auxologico Italiano class: OTHER name: Ministry of Health, Italy briefSummary: The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity.
Questionnaires for the evaluation of mood and symptoms will be collected upon enrollment, patient's anamnestic and clinical data relating to disease complications, BMI, previous blood tests, cortisol suppression with dexamethasone 1 mg will be collected, and blood sample will be sent to and analyzed at a centralized laboratory for the study of Steroid hormones, bone metabolism, lipoprotein function, genetics and receptor analysis. conditions: Obesity, Morbid studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: CROSS_SECTIONAL count: 180 type: ESTIMATED measure: Association of androgen milieu with the severity of obesity measure: Association of cortisol milieu with the severity of obesity measure: Algorithm fo CV risk in obesity measure: Prevalence of hypogonadism in morbid obesity measure: Prevalence of patients with morbid obesity unresponsive to overnight suppression test measure: Enrichment in rare HH variants in obese patients with central hypogonadism measure: Enrichment in rare variants associated with hypercortisolism in obese patients unresponsive to Nugent testing sex: MALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Auxlogico Italiano, Hospital San Giuseppe, Piancavallo status: RECRUITING city: Oggebbio state: Verbania zip: 28824 country: Italy name: Biagio Cangiano, MD role: CONTACT phone: 3343177491 email: b.cangiano@auxologico.it name: Massimo Scacchi, Professor role: CONTACT email: massimo.scacchi@unimi.it lat: 45.99088 lon: 8.64663 hasResults: False
nctId: NCT06341686 id: 75471023.2.0000.0082 briefTitle: Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection overallStatus: NOT_YET_RECRUITING date: 2024-05-05 date: 2025-03 date: 2025-05 date: 2024-04-02 date: 2024-04-02 name: Hospital do Rim e Hipertensão class: OTHER briefSummary: The two main cytomegalovirus (CMV) prevention strategies are prophylaxis and preemptive therapy. Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT), but is associated with high rates of neutropenia and late onset of post-prophylactic disease. In contrast, preemptive therapy has the advantage of leading to lower rates of CMV disease and robust humoral and T-cell responses. It is widely used in hematopoietic cell transplant recipients, but is rarely used after solid organ transplant recipients due to logistical considerations. conditions: CMV Infection studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1. Patients randomized to the prophylaxis group: Letermovir 480mg, 1x/day, from D14 to D98. Letermovir prophylaxis will start on day 14 after the kidney transplant.
2. Patients randomized to the preemptive treatment group: Preemptive treatment (PET) will begin on day 21, evaluating CMV DNAnemia weekly until D98.CMV DNAnemia weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98). The threshold for starting treatment with Ganciclovir is a CMV DNAemiaDNAemia \> 5,000 IU in a single measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (CMV syndrome or disease).
3. In both groups, CMV DNAemia will be monitored weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98), and after any acute rejection treatment occurring between 3 months and 6 months after kidney transplantation. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Letermovir 480 MG name: Ganciclovir measure: Incidence of CMV syndrome or disease measure: Incidence of patients with plasma CMV DNAemia > 200 IU measure: Incidence of patients with CMV infection/syndrome/disease sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341673 id: IRB-2023-O3-442 briefTitle: Impact of TTNS on Bladder Symptoms Among People With MS, A RCT overallStatus: RECRUITING date: 2024-03-15 date: 2024-04-28 date: 2024-06-30 date: 2024-04-02 date: 2024-04-02 name: Hawra Al-Dandan class: OTHER briefSummary: Background: Neurogenic lower urinary tract dysfunction is common among people with multiple sclerosis (MS). Recent studies showed that bladder storage symptoms are predominant among MS with a pooled prevalence of frequency at 73.45% followed by urgency at 63.87%. Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive treatment to manage bladder storage symptoms; however, the effectiveness of TTNS is based on a small number of studies with the absence of high-quality evidence. This study aims to investigate the effectiveness of TTNS on bladder storage symptoms compared with sham TTNS among people with MS.Methods: The investigators will use a randomised sham controlled double blind study to explore the effectiveness of TTNS in the treatment of bladder storage symptoms in MS. the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) was followed to standardize the conduct and reporting of the current protocol. The recruitment plan is twofold: 1) Open recruitment for people with MS through King Fahd Hospital of the University communication channels; 2) people with any type of MS attending their routine appointments in MS clinic at King Fahd Hospital of the University, Al Khobar. The investigators will investigate the effectiveness of TTNS compared to sham TTNS on bladder storage symptoms and the effect on quality of life using ICIQ-OAB, ICIQ 3-day bladder diary, ICIQ-LUTS qol, and PSQI. Participant's perception of change post intervention will be evaluated using GPE. Outcomes will be measured at 0, 6 weeks and at 6 months post intervention. A sample size of 72 patients (36 in each group) is required to achieve 90% power with two-tailed tests at an alpha level of 0.05.
Conclusion: Multiple sclerosis is a long-term condition, and self-management is important. TTNS provide a safe, non-invasive intervention that can be administered at home. Should the trial determine that TTNS is effective compared to sham TTNS, the investigators will plan to integrate TTNS into standard clinical care pathways in MS. conditions: Overactive Bladder Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, sham-controlled, double blind study with 1:1 allocation ratio. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Participants and those who undertake data input and data analysis will be blind to group allocation to reduce the risk of performance bias. A principal investigator and co-investigator will insert data into SPSS so that the researchers can analyse data without having access to the allocation. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 72 type: ESTIMATED name: Active Transcutaneous Electrical Nerve Stimulation (TENS) name: Sham Transcutaneous Electrical Nerve Stimulation (TENS) measure: The International Consultation of Incontinence Questionnaire- Overactive Bladder (ICIQ- OAB) measure: 3- day Bladder diary measure: Urinary sensation scale. measure: The International Consultation of incontinence Questionnaire, Lower Urinary Tract Symptoms, Quality of life (ICIQ - LUTS,Qol) measure: Pittsburgh Sleep Quality Index (PSQI)-item 6 measure: Global Perceived Effect (GPE) Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: King Fahd Hospital of the University status: RECRUITING city: Khobar state: Eastern Providence country: Saudi Arabia name: Dr Hawra Al Dandan, PhD role: CONTACT phone: +966555901977 email: hdandan@iau.edu.sa name: Dr Saad Al Saadi, PhD role: CONTACT phone: +966552519515 email: ssaadi@iau.edu.sa lat: 26.27944 lon: 50.20833 hasResults: False
nctId: NCT06341660 id: CROC202313 briefTitle: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) overallStatus: RECRUITING date: 2023-05-25 date: 2025-06 date: 2025-07 date: 2024-04-02 date: 2024-04-02 name: Guangzhou Institute of Respiratory Disease class: OTHER briefSummary: To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent non-small cell lung cancer. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: cadonilimab measure: Safety assessments and ORR sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Guangzhou Medical University status: RECRUITING city: Guangdong state: Guangzhou zip: 510000 country: China name: zhou chegnzhi, doctor role: CONTACT phone: 13560351186 email: doctorzcz@163.com hasResults: False
nctId: NCT06341647 id: AB-201-01 id: 103300 (HREC 233/23) type: OTHER domain: TGA (Australia) briefTitle: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2027-04 date: 2029-02 date: 2024-04-02 date: 2024-04-02 name: GC Cell Corporation class: INDUSTRY briefSummary: This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b. The primary objective of phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors. conditions: Breast Cancer conditions: Gastric Cancer conditions: Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: * Safety: incidence and severity of AE and SAE \[Time Frame: From the time of consent through End of Study (up to 18 months per patient)\]
* Determination of Recommended Phase 2 Dose (RP2D) primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: AB-201 name: Cyclophosphamide name: Fludarabine measure: Incidence, severity, seriousness, and dose relationship of Adverse Events [Safety & Tolerability] measure: Determination of Recommended Phase 2 Dose (RP2D) measure: To determine the preliminary efficacy, by the objective response rate (ORR) per the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1, of AB-201 in subjects with advanced HER2+ solid tumors sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peter MacCallum Cancer Centre city: Melbourne state: Victoria zip: 3000 country: Australia name: Michael Michael role: CONTACT phone: +6138559-5000 email: Michael.Michael@petermac.org lat: -37.814 lon: 144.96332 facility: The Alfred Hosptial city: Melbourne state: Victoria zip: 3004 country: Australia name: Mark Voskoboynik role: CONTACT phone: +613-9076-3129 email: m.voskoboynik@alfred.org.au lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06341634 id: VISIA id: TED2021-130747B-C22 type: OTHER_GRANT domain: European Union id: 3494130747-130747-28-521 type: OTHER domain: Ministry of Science and Innovation briefTitle: Surveillance of Suicide Ideation in Adolescents (VISIA) acronym: VISIA overallStatus: ENROLLING_BY_INVITATION date: 2024-02-06 date: 2024-11-24 date: 2024-11-24 date: 2024-04-02 date: 2024-04-02 name: Servicio Gallego de Salud class: OTHER_GOV name: University of Vigo name: Complejo Hospitalario Universitario de Vigo name: Complexo Hospitalario de Ourense name: Fundacin Biomedica Galicia Sur briefSummary: The goal of this observational study is to validate an AI algorithm's capability to differentiate the population with suicidal ideation from a control population using various multimodal variables, including voice analysis, facial emotions, natural language, and proteomics data.